SB-269970

SB-269970
Identifiers
	IUPAC name (2R)-1-[(3-Hydroxyphenyl)sulfonyl]-2 -(2-(4-methyl-1-piperidinyl)ethyl)pyrrolidine;
CAS Number	201038-74-6 ;
PubChem CID	6604889;
IUPHAR/BPS	3233;
ChemSpider	5037148;
ChEMBL	ChEMBL282199 ;
CompTox Dashboard (EPA)	DTXSID90942127 ;
Chemical and physical data
Formula	C18H28N2O3S
Molar mass	352.490 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC2CCN(CC2)CCC1CCCN1S(=O)(=O)c(c3)cccc3O;
	InChI InChI=1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3/t16-/m1/s1; Key:HWKROQUZSKPIKQ-MRXNPFEDSA-N;
	(what is this?) (verify)

SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It is believed to act as a selective 5-HT₇ receptor antagonist (EC₅₀ = 1.25 nM) (or possibly inverse agonist). A subsequent study in guinea pig at 10 uM showed that it also blocks the α₂-adrenergic receptor activity.^[1]^[2]^[3] The significant difference in test concentrations, however, confirms the selectivity of SB-269970 for the 5-HT₇ receptor.

SB-269970 is used to study the 5-HT₇ receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus,^[4] and regulation of dopamine release in the ventral tegmental area.^[5] Possible therapeutic uses for SB-269970 and other 5-HT₇ antagonists include the treatment of anxiety and depression,^[6]^[7] and nootropic effects have also been noted in animal studies.^[8]^[9]

References

^ Mahé C; Loetscher E; Feuerbach D; Müller W; Seiler MP; Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2–3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.
^ Lovell PJ, Bromidge SM, Dabbs S, et al. (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970)". J. Med. Chem. 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.
^ Foong JP; Bornstein JC. (2009). "5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig". NeuroReport. 20 (3): 325–330. doi:10.1097/WNR.0b013e3283232caa. PMID 19190523.
^ Thomas, DR; Hagan, JJ (2004). "5-HT7 receptors". Current drug targets. CNS and neurological disorders. 3 (1): 81–90. doi:10.2174/1568007043482633. PMID 14965246. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Mnie-Filali, O; Dahan, L; Zimmer, L; Haddjeri, N (2007). "Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine". European Journal of Pharmacology. 570 (1–3): 72–6. doi:10.1016/j.ejphar.2007.05.037. PMID 17586491. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Hedlund, PB; Huitron-Resendiz, S; Henriksen, SJ; Sutcliffe, JG (2005). "5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern". Biological Psychiatry. 58 (10): 831–7. doi:10.1016/j.biopsych.2005.05.012. PMID 16018977. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Wesołowska, A; Nikiforuk, A; Stachowicz, K; Tatarczyńska, E (2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–86. doi:10.1016/j.neuropharm.2006.04.017. PMID 16828124. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Gasbarri, A; Cifariello, A; Pompili, A; Meneses, A (2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–70. doi:10.1016/j.bbr.2007.12.020. PMID 18308404. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
^ Liy-Salmeron, G; Meneses, A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–74. doi:10.1002/hipo.20459. PMID 18570192. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

[pmid15249157-1] Mahé C; Loetscher E; Feuerbach D; Müller W; Seiler MP; Schoeffter P (2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". Eur. J. Pharmacol. 495 (2–3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.

[pmid10669560-2] Lovell PJ, Bromidge SM, Dabbs S, et al. (2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phenol (SB-269970)". J. Med. Chem. 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.

[pmid19190523-3] Foong JP; Bornstein JC. (2009). "5-HT antagonists NAN-190 and SB 269970 block alpha2-adrenoceptors in the guinea pig". NeuroReport. 20 (3): 325–330. doi:10.1097/WNR.0b013e3283232caa. PMID 19190523.

[4] Thomas, DR; Hagan, JJ (2004). "5-HT7 receptors". Current drug targets. CNS and neurological disorders. 3 (1): 81–90. doi:10.2174/1568007043482633. PMID 14965246. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[5] Mnie-Filali, O; Dahan, L; Zimmer, L; Haddjeri, N (2007). "Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine". European Journal of Pharmacology. 570 (1–3): 72–6. doi:10.1016/j.ejphar.2007.05.037. PMID 17586491. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[6] Hedlund, PB; Huitron-Resendiz, S; Henriksen, SJ; Sutcliffe, JG (2005). "5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern". Biological Psychiatry. 58 (10): 831–7. doi:10.1016/j.biopsych.2005.05.012. PMID 16018977. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[7] Wesołowska, A; Nikiforuk, A; Stachowicz, K; Tatarczyńska, E (2006). "Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression". Neuropharmacology. 51 (3): 578–86. doi:10.1016/j.neuropharm.2006.04.017. PMID 16828124. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[8] Gasbarri, A; Cifariello, A; Pompili, A; Meneses, A (2008). "Effect of 5-HT(7) antagonist SB-269970 in the modulation of working and reference memory in the rat". Behavioural Brain Research. 195 (1): 164–70. doi:10.1016/j.bbr.2007.12.020. PMID 18308404. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[9] Liy-Salmeron, G; Meneses, A (2008). "Effects of 5-HT drugs in prefrontal cortex during memory formation and the ketamine amnesia-model". Hippocampus. 18 (9): 965–74. doi:10.1002/hipo.20459. PMID 18570192. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]